Methodological Assessment of High-Throughput Sequencing Platforms: Illumina vs. MGI in Clinical-Grade CFTR Genotyping
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms262311701 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Marianna Beggio und 6 weiteren Autor:innen. Beteiligte Einrichtung: UOSD Genetica e Citogenetica, Dipartimento di Direzione Medica del Presidio Ospedaliero di Mestre, AULSS3 Serenissima, 30172 Venezia, Italy. Hauptthemen laut MEDLINE: Cystic Fibrosis Transmembrane Conductance Regulator, High-Throughput Nucleotide Sequencing, Cystic Fibrosis, Genotyping Techniques. Die Arbeit nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministero della Salute, Italian Ministry of Health.
Abstract (Originalsprache)
The growing demand for precision diagnostics in cystic fibrosis and other genetic disorders, such as cancers, is driving the need for sequencing platforms that combine analytical robustness, scalability, and cost-efficiency. In this study, we performed a direct comparison between two leading Next-Generation Sequencing (NGS) platforms, MiSeq (Illumina, CA, USA) and DNBSEQ-G99RS (MGI Tech Co., Shenzhen, China), using a CE-IVD-certified CFTR panel (Devyser AB), selected for its complexity and variant spectrum, including SNVs, CNVs, and intronic polymorphisms. A total of 47 genomic DNA samples from routine clinical activity were analyzed on both platforms. Illumina sequencing covered all CFTR variants using standard workflows, while MGI data were generated from residual diagnostic DNA, with informed consent. Sequencing data were processed using Amplicon Suite v3.7.0 for variant calling, annotation, and ACMG classification. Quality control metrics and platform-specific parameters were also evaluated. Both platforms demonstrated complete concordance in variant detection, including SNVs, CNVs, and complex alleles (e.g., Poly-T/TG). Illumina exhibited slightly superior basecalling quality and allelic frequency uniformity, while MGI achieved higher sequencing depth (mean ~2793×) and demultiplexing efficiency. No false positives, false negatives, or discordant HGVS annotations were observed. The use of full-gene CFTR sequencing enabled granular and technically rigorous cross-platform validation. These findings confirm the analytical equivalence of Illumina and MGI for diagnostic genotyping. Moreover, MGI’s greater data output and flow cell capacity may offer tangible advantages in high-throughput settings, including somatic applications such as liquid biopsy and molecular oncology workflows.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- UOSD Genetica e Citogenetica, Dipartimento di Direzione Medica del Presidio Ospedaliero di Mestre, AULSS3 Serenissima, 30172 Venezia, Italy.
- Immunology and Molecular Oncology Unit, Veneto Institute of Oncology, IOV-IRCCS, 35128 Padova, Italy.
- Department of Surgery Oncology and Gastroenterology, University of Padova, 35122 Padova, Italy.
ORCID-Profile: Marianna Beggio, Edoardo Peroni, Giulia Favretto, Dario Degiorgio, Antonio Rosato
Förderung
- Ministero della Salute
- Italian Ministry of Health
Zitieren
APA
Beggio, M., Peroni, E., Greco, E., Favretto, G., Degiorgio, D., Rosato, A., & Favarato, M. (2025). Methodological Assessment of High-Throughput Sequencing Platforms: Illumina vs. MGI in Clinical-Grade CFTR Genotyping. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms262311701
Vancouver
Beggio M, Peroni E, Greco E, Favretto G, Degiorgio D, Rosato A, et al. Methodological Assessment of High-Throughput Sequencing Platforms: Illumina vs. MGI in Clinical-Grade CFTR Genotyping. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms262311701
BibTeX
@article{Beggio2025,
author = {Beggio, Marianna and Peroni, Edoardo and Greco, Eliana and Favretto, Giulia and Degiorgio, Dario and Rosato, Antonio and Favarato, Mosè},
title = {Methodological Assessment of High-Throughput Sequencing Platforms: Illumina vs. MGI in Clinical-Grade CFTR Genotyping},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms262311701}
}
EUVIMED